Tiziana Life Sciences #TILS to present two studies featuring StemPrintER during the American Society of Clinical Oncology (ASCO) Virtual Conference May 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London – May 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announces that two abstracts on the Company’s stem cell biology-based genomic tool, StemPrintER, for the prediction of disease recurrence in breast cancer patients, will be presented at the American Society of Clinical Oncology’s 2020 Virtual Conference. All abstracts, including Abstract #1020, which compares Tiziana’s product to…

Tiziana Life Sciences #TILS – Result of GM May 6, 2020 – Posted in: Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION At the General Meeting of the Company held at 11.00 a.m. on 6 May 2020, the resolutions to seek additional authorities to issue…

Tiziana Life Sciences #TILS – Block Listing Application and “At The Market” Sales Agreement April 15, 2020 – Posted in: Tiziana Life Sciences (TILS)

London / New York 15 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that that it has entered into an “At the Market” or “ATM” Sales Agreement with Think Equity (a division of Fordham Financial Management, Inc.) to raise up to…

Tiziana Life Sciences #TILS – Proposed US Public Offering August 6, 2019 – Posted in: Tiziana Life Sciences (TILS)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Tiziana Announces Publication of Registration Statement on Form F-1 and Proposed U.S. Public Offering of ADSs New York and London, August 6, 2019 – Tiziana Life Sciences…

Tiziana Life Sciences (TILS) Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in patients with advanced Hepatocellular Carcinoma liver cancer July 21, 2019 – Posted in: Tiziana Life Sciences (TILS)

Milciclib was well tolerated and no drug related deaths were reported 28 out 31 treated patients were evaluable, with 14 patients completing the 6-month study duration 9 patients continued treatment under compassionate use, of which 5 are currently continuing with treatment New York/London, 22 July 2019 – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced…

Tiziana Life Sciences #TILS to present two studies featuring StemPrintER during the American Society of Clinical Oncology (ASCO) Virtual Conference May 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences #TILS – Result of GM May 6, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences #TILS – Block Listing Application and “At The Market” Sales Agreement April 15, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences #TILS – Proposed US Public Offering August 6, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences (TILS) Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in patients with advanced Hepatocellular Carcinoma liver cancer July 21, 2019 – Posted in: Tiziana Life Sciences (TILS)

Address

Contact

Social

LEGAL